MRM Health Starts Clinical Trial with Next-Generation Optimized Consortium Therapeutic MH002 in Pouchitis
Present CEO, Niklas Ahlborg, will remain at the company as a Senior Advisor.
This investment builds on a long-standing collaboration in biocontrol and pollination which began in 1992.
The business purpose of the new joint venture is to promote Ceva’s image and business strategy to potential Japanese partners.
The goal of Oncode-PACT is to create a state-of-the-art drug development infrastructure to innovate the cancer drug development process itself.
Ceva acquired the veterinary biopharmaceutical and R&D activities of IDT Biologika based at the Dessau site in 2019.
